Human Pancreatic Cancer Cells Induce a MyD88-Dependent Stromal Response to Promote a Tumor-Tolerant Immune Microenvironment.

Cancer cells exert mastery over the local tumor-associated stroma (TAS) to configure protective immunity within the tumor microenvironment. The immunomodulatory character of pancreatic lysates of patients with cancer differs from those with pancreatitis. In this study, we evaluated the cross-talk between pancreatic cancer and its TAS in primary human cell culture models. Upon exposure of TAS to pancreatic cancer cell-conditioned media, we documented robust secretion of IL6 and IL8. This TAS response was MyD88-dependent and sufficient to directly suppress both CD4+ and CD8+ T-cell proliferation, inducing Th17 polarization at the expense of Th1. We found that patients possessed a similar shift in circulating effector memory Th17:Th1 ratios compared with healthy controls. The TAS response also directly suppressed CD8+ T-cell-mediated cytotoxicity. Overall, our results demonstrate how TAS contributes to the production of an immunosuppressive tumor microenvironment in pancreatic cancer. Cancer Res; 77(3); 672-83. ©2016 AACR.

[1]  S. Wallet,et al.  Isolation of Pancreatic Cancer Cells from a Patient-Derived Xenograft Model Allows for Practical Expansion and Preserved Heterogeneity in Culture. , 2016, The American journal of pathology.

[2]  Y. Thanavala,et al.  High immunosuppressive burden in cancer patients: a major hurdle for cancer immunotherapy , 2016, Cancer Immunology, Immunotherapy.

[3]  G. Sarosi,et al.  The inflammatory milieu within the pancreatic cancer microenvironment correlates with clinicopathologic parameters, chemoresistance and survival , 2015, BMC Cancer.

[4]  E. Jaffee,et al.  TGF-β blockade depletes T regulatory cells from metastatic pancreatic tumors in a vaccine dependent manner , 2015, Oncotarget.

[5]  L. Moldawer,et al.  Downstream mediators of the intratumoral interferon response suppress antitumor immunity, induce gemcitabine resistance and associate with poor survival in human pancreatic cancer , 2015, Cancer Immunology, Immunotherapy.

[6]  M. Karin,et al.  Immunity, inflammation, and cancer: an eternal fight between good and evil. , 2015, The Journal of clinical investigation.

[7]  G. Sarosi,et al.  Primary outgrowth cultures are a reliable source of human pancreatic stellate cells , 2015, Laboratory Investigation.

[8]  Y. Kanai,et al.  Intratumoral tertiary lymphoid organ is a favourable prognosticator in patients with pancreatic cancer , 2015, British Journal of Cancer.

[9]  G. Sarosi,et al.  Patient-derived xenograft models for pancreatic adenocarcinoma demonstrate retention of tumor morphology through incorporation of murine stromal elements. , 2015, The American journal of pathology.

[10]  E. Furth,et al.  Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma , 2015, Cancer Immunology Research.

[11]  K. Matsushima,et al.  Robust Antitumor Effects of Combined Anti–CD4-Depleting Antibody and Anti–PD-1/PD-L1 Immune Checkpoint Antibody Treatment in Mice , 2015, Cancer Immunology Research.

[12]  A. Amedei,et al.  Pancreatic cancer: Role of the immune system in cancer progression and vaccine-based immunotherapy , 2014, Human vaccines & immunotherapeutics.

[13]  G. Wahl,et al.  Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy , 2014, Cell.

[14]  I. Pinchuk,et al.  TLR4 Activation Enhances the PD-L1–Mediated Tolerogenic Capacity of Colonic CD90+ Stromal Cells , 2014, The Journal of Immunology.

[15]  R. Hruban,et al.  Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation , 2014, Cancer Immunology Research.

[16]  Umar Mahmood,et al.  Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. , 2014, Cancer cell.

[17]  Stephen A. Sastra,et al.  Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. , 2014, Cancer cell.

[18]  A. Maitra,et al.  A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice. , 2014, Gastroenterology.

[19]  Benjamin D. Smith,et al.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.

[20]  A. Maitra,et al.  Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia. , 2014, Cancer cell.

[21]  Z. Trajanoski,et al.  Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. , 2013, Immunity.

[22]  D. Lobo,et al.  The presence of tumour-associated lymphocytes confers a good prognosis in pancreatic ductal adenocarcinoma: an immunohistochemical study of tissue microarrays , 2013, BMC Cancer.

[23]  S. Martin,et al.  Danger signalling during cancer cell death: origins, plasticity and regulation , 2013, Cell Death and Differentiation.

[24]  Jonathan B. Mitchem,et al.  Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Axis , 2013, Clinical Cancer Research.

[25]  J. Furuse,et al.  Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer , 2013, British Journal of Cancer.

[26]  G. Trinchieri,et al.  Molecular Pathways Molecular Pathways : Toll-like Receptors in the Tumor Microenvironment — Poor Prognosis or New Therapeutic Opportunity , 2013 .

[27]  Alexander A. Fingerle,et al.  The role of stroma in pancreatic cancer: diagnostic and therapeutic implications , 2012, Nature Reviews Gastroenterology &Hepatology.

[28]  Yan Liu,et al.  An NF-κB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice. , 2012, The Journal of clinical investigation.

[29]  Wei Hu,et al.  Priming microenvironments dictate cytokine requirements for T helper 17 cell lineage commitment. , 2011, Immunity.

[30]  D. Baltimore,et al.  Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells , 2011, Proceedings of the National Academy of Sciences.

[31]  H. Friess,et al.  StellaTUM: current consensus and discussion on pancreatic stellate cell research , 2011, Gut.

[32]  M. Braga,et al.  Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer , 2011, The Journal of experimental medicine.

[33]  S. Rosenberg,et al.  Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma , 2010, Journal of immunotherapy.

[34]  Yuan Tian,et al.  Expression and significance of TLR4 and HIF-1alpha in pancreatic ductal adenocarcinoma. , 2010, World journal of gastroenterology.

[35]  C. Erridge.  Endogenous ligands of TLR2 and TLR4: agonists or assistants? , 2010, Journal of leukocyte biology.

[36]  Maria T. Abreu,et al.  Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function , 2010, Nature Reviews Immunology.

[37]  Yusuke Sato,et al.  Cancer Cells Expressing Toll-like Receptors and the Tumor Microenvironment , 2009, Cancer Microenvironment.

[38]  S. Youssef,et al.  Differential Regulation of Chemokines by IL-17 in Colonic Epithelial Cells1 , 2008, The Journal of Immunology.

[39]  Helmut Friess,et al.  The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[40]  D. Tuveson,et al.  Dynamics of the immune reaction to pancreatic cancer from inception to invasion. , 2007, Cancer research.

[41]  Weiping Zou,et al.  Immunosuppressive networks in the tumour environment and their therapeutic relevance , 2005, Nature Reviews Cancer.

[42]  H. Moses,et al.  Stromal fibroblasts in cancer initiation and progression , 2004, Nature.

[43]  Dirk E. Smith,et al.  Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction , 2001, Nature.

[44]  V. Engelhard,et al.  Perforin-dependent cytotoxic activity and lymphokine secretion by CD4+ T cells are regulated by CD8+ T cells. , 1997, Journal of immunology.

[45]  Jian Ye,et al.  The role and regulation of human Th17 cells in tumor immunity. , 2013, The American journal of pathology.

[46]  Holden T. Maecker,et al.  Erratum: Standardizing immunophenotyping for the Human Immunology Project , 2012, Nature Reviews Immunology.

[47]  M. Willson,et al.  CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans , 2011 .

[48]  Deborah M. Brown,et al.  IL-2 and antigen dose differentially regulate perforin- and FasL-mediated cytolytic activity in antigen specific CD4+ T cells. , 2009, Cellular immunology.

[49]  F. Marincola,et al.  Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. , 2000, Advances in immunology.